

LUCERNE STUDY

...for wet macular degeneration



Wet Macular Degeneration

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration

Principal Investigator:
Matthew Ohr, MD

Inclusion Criteria:

- You are at least 50 years of age
- You have been diagnosed with wet age-related macular degeneration
- Your best-corrected visual acuity is 78 to 24 letters, inclusive (20/32 to 20/320 approximate Snellen equivalent)

Exclusion criteria

- You have received prior treatment for wet AMD or have had intraocular surgery
- You have had active cancer within the past 12 months
- You have a history of a stroke or heart attack within the past six months
- You have uncontrolled glaucoma or high blood pressure (systolic > 180mmHg; diastolic > 100mmHg)

Havener Eye Institute Research Office • 614-293-5287 • Research@osumc.edu

This research is not being conducted by the Columbus Chalmers P. Wiley Ambulatory Care Center. The research has not been reviewed by the Institutional Review Board of the Chalmers P. Wiley VA. The VA is not responsible for any costs incurred by participating in the research study.